Literature DB >> 22710362

Molecular biology and genetic diversity of Rift Valley fever virus.

Tetsuro Ikegami1.   

Abstract

Rift Valley fever virus (RVFV), a member of the family Bunyaviridae, genus Phlebovirus, is the causative agent of Rift Valley fever (RVF), a mosquito-borne disease of ruminant animals and humans. The generation of a large sequence database has facilitated studies of the evolution and spread of the virus. Bayesian analyses indicate that currently circulating strains of RVFV are descended from an ancestral species that emerged from a natural reservoir in Africa when large-scale cattle and sheep farming were introduced during the 19th century. Viruses descended from multiple lineages persist in that region, through infection of reservoir animals and vertical transmission in mosquitoes, emerging in years of heavy rainfall to cause epizootics and epidemics. On a number of occasions, viruses from these lineages have been transported outside the enzootic region through the movement of infected animals or mosquitoes, triggering outbreaks in countries such as Egypt, Saudi Arabia, Mauritania and Madagascar, where RVF had not previously been seen. Such viruses could potentially become established in their new environments through infection of wild and domestic ruminants and other animals and vertical transmission in local mosquito species. Despite their extensive geographic dispersion, all strains of RVFV remain closely related at the nucleotide and amino acid level. The high degree of conservation of genes encoding the virion surface glycoproteins suggests that a single vaccine should protect against all currently circulating RVFV strains. Similarly, preservation of the sequence of the RNA-dependent RNA polymerase across viral lineages implies that antiviral drugs targeting the enzyme should be effective against all strains. Researchers should be encouraged to collect additional RVFV isolates and perform whole-genome sequencing and phylogenetic analysis, so as to enhance our understanding of the continuing evolution of this important virus. This review forms part of a series of invited papers in Antiviral Research on the genetic diversity of emerging viruses.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22710362      PMCID: PMC3586937          DOI: 10.1016/j.antiviral.2012.06.001

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  102 in total

1.  Loop-mediated isothermal amplification of DNA.

Authors:  T Notomi; H Okayama; H Masubuchi; T Yonekawa; K Watanabe; N Amino; T Hase
Journal:  Nucleic Acids Res       Date:  2000-06-15       Impact factor: 16.971

2.  Possible Rift Valley fever outbreak in man and cattle in Madagascar.

Authors:  J Morvan; D Fontenille; J F Saluzzo; P Coulanges
Journal:  Trans R Soc Trop Med Hyg       Date:  1991 Jan-Feb       Impact factor: 2.184

3.  Rift valley fever virus nonstructural protein NSs promotes viral RNA replication and transcription in a minigenome system.

Authors:  Tetsuro Ikegami; C J Peters; Shinji Makino
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  International network for capacity building for the control of emerging viral vector-borne zoonotic diseases: ARBO-ZOONET.

Authors:  J Ahmed; M Bouloy; O Ergonul; Ar Fooks; J Paweska; V Chevalier; C Drosten; R Moormann; N Tordo; Z Vatansever; P Calistri; A Estrada-Pena; A Mirazimi; H Unger; H Yin; U Seitzer
Journal:  Euro Surveill       Date:  2009-03-26

5.  Detection of Rift Valley fever virus in mosquitoes by RT-PCR.

Authors:  M S Ibrahim; M J Turell; F K Knauert; R S Lofts
Journal:  Mol Cell Probes       Date:  1997-02       Impact factor: 2.365

6.  Detection and identification of Toscana and other phleboviruses by RT-nested-PCR assays with degenerated primers.

Authors:  María-Paz Sánchez-Seco; José-Manuel Echevarría; Lourdes Hernández; Domingo Estévez; José-María Navarro-Marí; Antonio Tenorio
Journal:  J Med Virol       Date:  2003-09       Impact factor: 2.327

7.  Single-tube and nested reverse transcriptase-polymerase chain reaction for detection of Rift Valley fever virus in human and animal sera.

Authors:  A A Sall; J Thonnon; O K Sene; A Fall; M Ndiaye; B Baudez; C Mathiot; M Bouloy
Journal:  J Virol Methods       Date:  2001-01       Impact factor: 2.014

8.  Rift valley fever virus L protein forms a biologically active oligomer.

Authors:  Aya Zamoto-Niikura; Kaori Terasaki; Tetsuro Ikegami; C J Peters; Shinji Makino
Journal:  J Virol       Date:  2009-10-07       Impact factor: 5.103

9.  Purifying selection can obscure the ancient age of viral lineages.

Authors:  Joel O Wertheim; Sergei L Kosakovsky Pond
Journal:  Mol Biol Evol       Date:  2011-06-24       Impact factor: 16.240

10.  Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins.

Authors:  Sonja R Gerrard; Stuart T Nichol
Journal:  Virology       Date:  2006-09-08       Impact factor: 3.616

View more
  59 in total

1.  The genetic basis for susceptibility to Rift Valley fever disease in MBT/Pas mice.

Authors:  S Tokuda; T Z Do Valle; L Batista; D Simon-Chazottes; L Guillemot; M Bouloy; M Flamand; X Montagutelli; J-J Panthier
Journal:  Genes Immun       Date:  2015-01-08       Impact factor: 2.676

2.  Large-scale recoding of an arbovirus genome to rebalance its insect versus mammalian preference.

Authors:  Sam H Shen; Charles B Stauft; Oleksandr Gorbatsevych; Yutong Song; Charles B Ward; Alisa Yurovsky; Steffen Mueller; Bruce Futcher; Eckard Wimmer
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

3.  The two faces of Rift Valley fever virus virulence factor NSs: The development of a vaccine and the elucidation of pathogenesis.

Authors:  Satoko Yamaoka; Hideki Ebihara
Journal:  Virulence       Date:  2016-07-18       Impact factor: 5.882

4.  Isolation and phylogenetic study of Rift Valley fever virus from the first imported case to China.

Authors:  Yongxia Shi; Kui Zheng; Xiaobo Li; Liqiang Li; Shufen Li; Jinmin Ma; Jun Dai; Jingkai Ji; Shuai Yuan; Haorong Lu; Jiandong Li; Fangfang Sun; Xun Xu; Jicheng Huang
Journal:  Virol Sin       Date:  2017-06       Impact factor: 4.327

5.  Coupling Vector-host Dynamics with Weather Geography and Mitigation Measures to Model Rift Valley Fever in Africa.

Authors:  B H McMahon; C A Manore; J M Hyman; M X LaBute; J M Fair
Journal:  Math Model Nat Phenom       Date:  2014-01-01       Impact factor: 4.157

6.  Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.

Authors:  Tetsuro Ikegami; Terence E Hill; Jennifer K Smith; Lihong Zhang; Terry L Juelich; Bin Gong; Olga A L Slack; Hoai J Ly; Nandadeva Lokugamage; Alexander N Freiberg
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

7.  Reverse genetics system for severe fever with thrombocytopenia syndrome virus.

Authors:  Benjamin Brennan; Ping Li; Shuo Zhang; Aqian Li; Mifang Liang; Dexin Li; Richard M Elliott
Journal:  J Virol       Date:  2014-12-31       Impact factor: 5.103

8.  Modifying the NSs gene to improve live-attenuated vaccine for Rift Valley fever.

Authors:  Olga Lihoradova; Tetsuro Ikegami
Journal:  Expert Rev Vaccines       Date:  2012-11       Impact factor: 5.217

9.  The NSs Protein Encoded by the Virulent Strain of Rift Valley Fever Virus Targets the Expression of Abl2 and the Actin Cytoskeleton of the Host, Affecting Cell Mobility, Cell Shape, and Cell-Cell Adhesion.

Authors:  Aline Bamia; Vasco Marcato; Magali Boissière; Zeyni Mansuroglu; Carole Tamietti; Mattea Romani; Dominique Simon; Guanfang Tian; Florence Niedergang; Jean-Jacques Panthier; Marie Flamand; Sylvie Souès; Eliette Bonnefoy
Journal:  J Virol       Date:  2020-12-09       Impact factor: 5.103

10.  Countermeasure development for Rift Valley fever: deletion, modification or targeting of major virulence factor NSs.

Authors:  Olga Lihoradova; Tetsuro Ikegami
Journal:  Future Virol       Date:  2014-01-01       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.